Ratings by JPMorgan (Eric Joseph)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/10/2025 | Kymera Therapeutics | KYMR | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/20/2025 | Revolution | RVMD | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/18/2025 | Novavax | NVAX | Maintain | Underweight (Underweight) |
|
Details | ||
| 11/18/2025 | Rocket Pharmaceuticals | RCKT | Downgrade | Underweight (Neutral) |
3.04 (4.41) |
45.07% | Details | |
| 9/16/2025 | CAMP4 Therapeutics Corp | CAMP | Downgrade | Neutral (Overweight) |
3.25 (4.20) |
29.23% | Details | |
| 8/7/2025 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/28/2025 | Rocket Pharmaceuticals | RCKT | Downgrade | Neutral (Overweight) |
2.33 (3.04) |
30.47% | Details | |
| 5/27/2025 | Rocket Pharmaceuticals | RCKT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/20/2025 | Prime Medicine | PRME | Downgrade | Neutral (Overweight) |
1.59 (4.01) |
152.2% | Details | |
| 5/19/2025 | Novavax | NVAX | Maintain | Underweight (N/A) |
|
Details | ||
| 5/16/2025 | CAMP4 Therapeutics Corp | CAMP | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/16/2025 | Septerna Inc | SEPN | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/13/2025 | Relay Therapeutics | RLAY | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/12/2025 | Kymera Therapeutics | KYMR | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/12/2025 | Terns Pharmaceuticals | TERN | Maintain | Neutral (Neutral) |
|
Details | ||
| 5/9/2025 | Novavax | NVAX | Maintain | Underweight (Underweight) |
|
Details | ||
| 5/7/2025 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 4/25/2025 | Opko Health | OPK | New Coverage | Neutral (N/A) |
1.47 (1.28) |
-12.93% | Details | |
| 4/15/2025 | Verve Therapeutics | VERV | Maintain | Neutral (Neutral) |
|
Details | ||
| 3/31/2025 | PTC Therapeutics | PTCT | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/14/2025 | PTC Therapeutics | PTCT | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/4/2025 | WAVE Life Sciences | WVE | Maintain | Overweight (N/A) |
|
Details | ||
| 3/3/2025 | Verve Therapeutics | VERV | Maintain | Neutral (Neutral) |
|
Details | ||
| 2/28/2025 | PTC Therapeutics | PTCT | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/24/2025 | bluebird bio | BLUE | Upgrade | Neutral (Underweight) |
7.04 (4.97) |
-29.4% | Details | |
| 2/18/2025 | Septerna Inc | SEPN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/11/2025 | Enanta Pharmaceuticals | ENTA | Maintain | Underweight (Underweight) |
|
Details | ||
| 2/10/2025 | Pliant Therapeutics | PLRX | Downgrade | Neutral (Overweight) |
7.79 (1.53) |
-80.36% | Details | |
| 1/29/2025 | Nurix | NRIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/8/2025 | Vir Biotechnology | VIR | Maintain | Neutral (N/A) |
|
Details | ||
| 12/2/2024 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/19/2024 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/19/2024 | Septerna Inc | SEPN | New Coverage | Overweight (N/A) |
22.53 (28.78) |
27.74% | Details | |
| 11/15/2024 | bluebird bio | BLUE | Downgrade | Underweight (Neutral) |
0.38 (4.97) |
1207.89% | Details | |
| 11/8/2024 | Monte Rosa Therapeutics | GLUE | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2024 | Revolution | RVMD | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2024 | Beam Therapeutics Inc | BEAM | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2024 | CAMP4 Therapeutics Corp | CAMP | New Coverage | Overweight (N/A) |
10.05 (3.25) |
-67.66% | Details | |
| 10/1/2024 | IGM Biosciences | IGMS | Downgrade | Underweight (Neutral) |
16.54 (1.27) |
-92.32% | Details | |
| 9/27/2024 | WAVE Life Sciences | WVE | New Coverage | Overweight (N/A) |
9.01 (13.12) |
45.62% | Details | |
| 9/10/2024 | Relay Therapeutics | RLAY | Maintain | Overweight (N/A) |
|
Details | ||
| 9/9/2024 | WAVE Life Sciences | WVE | New Coverage | Overweight (N/A) |
5.23 (9.01) |
72.28% | Details | |
| 8/15/2024 | IGM Biosciences | IGMS | Maintain | Neutral (N/A) |
|
Details | ||
| 8/15/2024 | bluebird bio | BLUE | Downgrade | Neutral (Overweight) |
1.06 (0.38) |
-64.15% | Details | |
| 8/12/2024 | Novavax | NVAX | Maintain | Underweight (N/A) |
|
Details | ||
| 8/8/2024 | Revolution | RVMD | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2024 | Relay Therapeutics | RLAY | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2024 | Beam Therapeutics Inc | BEAM | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2024 | TG Therapeutics | TGTX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/6/2024 | Enanta Pharmaceuticals | ENTA | Maintain | Underweight (N/A) |
|
Details | ||
| 7/30/2024 | Novavax | NVAX | Downgrade | Underweight (Neutral) |
17.11 (9.98) |
-41.67% | Details | |
| 7/16/2024 | Revolution | RVMD | Maintain | Overweight (N/A) |
|
Details | ||
| 7/8/2024 | HilleVax, Inc. | HLVX | Downgrade | Overweight (Neutral) |
14.06 (2.09) |
-85.14% | Details | |
| 6/20/2024 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 6/17/2024 | Nurix | NRIX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/21/2024 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/13/2024 | Prime Medicine | PRME | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2024 | Novavax | NVAX | Upgrade | Neutral (Underweight) |
4.47 (9.98) |
123.27% | Details | |
| 5/3/2024 | Vir Biotechnology | VIR | Maintain | Neutral (N/A) |
|
Details | ||
| 5/3/2024 | Biomea Fusion Inc. | BMEA | Maintain | Neutral (N/A) |
|
Details | ||
| 4/10/2024 | Nurix | NRIX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/2/2024 | Biomea Fusion Inc. | BMEA | Downgrade | Neutral (Overweight) |
14.95 (1.29) |
-91.37% | Details | |
| 2/27/2024 | Verve Therapeutics | VERV | Maintain | Neutral (N/A) |
|
Details | ||
| 2/27/2024 | Beam Therapeutics Inc | BEAM | Maintain | Overweight (N/A) |
|
Details | ||
| 2/23/2024 | Vir Biotechnology | VIR | Maintain | Neutral (N/A) |
|
Details | ||
| 2/23/2024 | Kymera Therapeutics | KYMR | Maintain | Overweight (N/A) |
|
Details | ||
| 2/16/2024 | Nurix | NRIX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/8/2024 | Enanta Pharmaceuticals | ENTA | Maintain | Underweight (N/A) |
|
Details | ||
| 2/5/2024 | TG Therapeutics | TGTX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/5/2024 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 1/29/2024 | Vir Biotechnology | VIR | Downgrade | Neutral (Overweight) |
9.70 (9.55) |
-1.55% | Details | |
| 1/29/2024 | Beam Therapeutics Inc | BEAM | Upgrade | Overweight (Neutral) |
24.92 (26.54) |
6.5% | Details | |
| 1/29/2024 | C4 Therapeutics | CCCC | Upgrade | Neutral (Underweight) |
5.69 (3.04) |
-46.57% | Details | |
| 1/4/2024 | Kymera Therapeutics | KYMR | Upgrade | Overweight (Neutral) |
22.90 (83.49) |
264.59% | Details | |
| 12/6/2023 | IGM Biosciences | IGMS | Maintain | Neutral (N/A) |
|
Details | ||
| 11/10/2023 | Pliant Therapeutics | PLRX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/10/2023 | HilleVax, Inc. | HLVX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/9/2023 | Monte Rosa Therapeutics | GLUE | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2023 | Prime Medicine | PRME | Maintain | Overweight (N/A) |
|
Details | ||
| 10/19/2023 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 10/17/2023 | Rocket Pharmaceuticals | RCKT | Maintain | Neutral (N/A) |
|
Details | ||
| 10/10/2023 | Akero Therapeutics | AKRO | Maintain | Overweight (N/A) |
|
Details | ||
| 10/9/2023 | Mirati Therapeutics | MRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 9/15/2023 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 8/28/2023 | Lyell Immunopharma | LYEL | Downgrade | Neutral (Overweight) |
2.23 (22.46) |
907.17% | Details | |
| 8/28/2023 | Century Therapeutics | IPSC | Downgrade | Neutral (Overweight) |
2.40 (2.56) |
6.67% | Details | |
| 8/10/2023 | Pliant Therapeutics | PLRX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/10/2023 | Atea Pharmaceuticals | AVIR | Downgrade | Underweight (Neutral) |
3.41 (5.89) |
72.73% | Details | |
| 8/9/2023 | Terns Pharmaceuticals | TERN | Maintain | Neutral (N/A) |
|
Details | ||
| 8/9/2023 | Enanta Pharmaceuticals | ENTA | Downgrade | Underweight (N/A) |
18.52 (11.93) |
-35.58% | Details | |
| 8/9/2023 | Mirati Therapeutics | MRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/7/2023 | TG Therapeutics | TGTX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/3/2023 | Kymera Therapeutics | KYMR | Maintain | Neutral (N/A) |
|
Details | ||
| 7/21/2023 | Vir Biotechnology | VIR | Maintain | Overweight (N/A) |
|
Details | ||
| 6/26/2023 | Biomea Fusion Inc. | BMEA | Maintain | Overweight (N/A) |
|
Details | ||
| 6/20/2023 | Biomea Fusion Inc. | BMEA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/25/2023 | Mirati Therapeutics | MRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 5/16/2023 | IGM Biosciences | IGMS | Maintain | Neutral (N/A) |
|
Details | ||
| 5/16/2023 | HilleVax, Inc. | HLVX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/16/2023 | Terns Pharmaceuticals | TERN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/12/2023 | Monte Rosa Therapeutics | GLUE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/9/2023 | Revolution | RVMD | Maintain | Overweight (N/A) |
|
Details | ||
| 5/8/2023 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/5/2023 | Autolus Therapeutics plc | AUTL | Maintain | Neutral (N/A) |
|
Details | ||
| 5/2/2023 | TG Therapeutics | TGTX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/28/2023 | bluebird bio | BLUE | New Coverage | Overweight (N/A) |
3.68 (1.06) |
-71.2% | Details | |
| 4/19/2023 | Relay Therapeutics | RLAY | Maintain | Overweight (N/A) |
|
Details | ||
| 4/17/2023 | Rocket Pharmaceuticals | RCKT | Maintain | Neutral (N/A) |
|
Details | ||
| 4/5/2023 | Relay Therapeutics | RLAY | Maintain | Overweight (N/A) |
|
Details | ||
| 4/3/2023 | IGM Biosciences | IGMS | Maintain | Neutral (N/A) |
|
Details | ||
| 3/29/2023 | Terns Pharmaceuticals | TERN | Maintain | Neutral (N/A) |
|
Details | ||
| 3/28/2023 | Biomea Fusion Inc. | BMEA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/17/2023 | Monte Rosa Therapeutics | GLUE | Maintain | (Overweight) |
|
Details | ||
| 3/15/2023 | Biomea Fusion Inc. | BMEA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/7/2023 | Autolus Therapeutics plc | AUTL | Maintain | Neutral (N/A) |
|
Details | ||
| 3/6/2023 | Vir Biotechnology | VIR | Upgrade | Overweight (Neutral) |
22.61 (9.55) |
-57.76% | Details | |
| 3/1/2023 | Beam Therapeutics Inc | BEAM | Maintain | Neutral (N/A) |
|
Details | ||
| 3/1/2023 | Mirati Therapeutics | MRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 2/28/2023 | Revolution | RVMD | Upgrade | Overweight (Neutral) |
24.33 (98.40) |
304.44% | Details | |
| 2/24/2023 | C4 Therapeutics | CCCC | Downgrade | Underweight (Neutral) |
5.92 (3.04) |
-48.65% | Details | |
| 2/22/2023 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/13/2023 | Nurix | NRIX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/9/2023 | Ironwood Pharmaceuticals | IRWD | Maintain | Neutral (N/A) |
|
Details | ||
| 2/8/2023 | Enanta Pharmaceuticals | ENTA | Maintain | Neutral (N/A) |
|
Details | ||
| 1/10/2023 | Rocket Pharmaceuticals | RCKT | Maintain | Neutral (N/A) |
|
Details | ||
| 12/16/2022 | Ironwood Pharmaceuticals | IRWD | Maintain | Neutral (N/A) |
|
Details | ||
| 12/14/2022 | Mirati Therapeutics | MRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 12/8/2022 | Mirati Therapeutics | MRTX | Downgrade | Neutral (Overweight) |
71.52 (58.70) |
-17.93% | Details | |
| 12/7/2022 | Pliant Therapeutics | PLRX | New Coverage | Overweight (N/A) |
17.00 (7.79) |
-54.18% | Details | |
| 12/6/2022 | Mirati Therapeutics | MRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/29/2022 | Surrozen Inc. | SRZN | Downgrade | Underweight (Neutral) |
0.82 (27.04) |
3197.56% | Details | |
| 11/14/2022 | Prime Medicine | PRME | New Coverage | Overweight (N/A) |
20.57 (1.59) |
-92.27% | Details | |
| 11/4/2022 | Kymera Therapeutics | KYMR | Maintain | Neutral (N/A) |
|
Details | ||
| 11/4/2022 | Karyopharm Therapeutics | KPTI | Maintain | Neutral (N/A) |
|
Details | ||
| 11/4/2022 | C4 Therapeutics | CCCC | Downgrade | Neutral (Overweight) |
9.70 (3.04) |
-68.66% | Details | |
| 10/28/2022 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 10/17/2022 | Livent Corp. | LTHM | New Coverage | Neutral (N/A) |
28.51 (16.51) |
-42.09% | Details | |
| 10/17/2022 | Surrozen Inc. | SRZN | New Coverage | Neutral (N/A) |
2.40 (27.04) |
1026.67% | Details | |
| 10/17/2022 | IGM Biosciences | IGMS | New Coverage | Neutral (N/A) |
21.83 (16.54) |
-24.23% | Details | |
| 9/26/2022 | Mirati Therapeutics | MRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/22/2022 | Novavax | NVAX | Downgrade | Underweight (Neutral) |
27.46 (4.47) |
-83.72% | Details | |
| 8/4/2022 | Karyopharm Therapeutics | KPTI | Maintain | Neutral (N/A) |
|
Details | ||
| 8/2/2022 | Mirati Therapeutics | MRTX | New Coverage | Overweight (N/A) |
64.40 (58.70) |
-8.85% | Details | |
| 8/2/2022 | Lyell Immunopharma | LYEL | New Coverage | Overweight (N/A) |
5.57 (22.46) |
303.23% | Details | |
| 8/2/2022 | Biomea Fusion Inc. | BMEA | New Coverage | Overweight (N/A) |
10.60 (1.39) |
-86.89% | Details | |
| 6/21/2022 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/24/2022 | HilleVax, Inc. | HLVX | New Coverage | Overweight (N/A) |
10.17 (14.06) |
38.25% | Details | |
| 5/19/2022 | Rocket Pharmaceuticals | RCKT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/5/2022 | Ironwood Pharmaceuticals | IRWD | Maintain | Neutral (N/A) |
|
Details | ||
| 4/18/2022 | TG Therapeutics | TGTX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/23/2022 | Enanta Pharmaceuticals | ENTA | Maintain | Neutral (N/A) |
|
Details | ||
| 3/23/2022 | Terns Pharmaceuticals | TERN | Downgrade | Neutral (Overweight) |
3.06 (42.82) |
1299.35% | Details | |
| 3/15/2022 | Verve Therapeutics | VERV | Maintain | Neutral (N/A) |
|
Details | ||
| 3/14/2022 | Aligos Therapeutics Inc. | ALGS | Maintain | Neutral (N/A) |
|
Details | ||
| 3/10/2022 | Kymera Therapeutics | KYMR | New Coverage | Neutral (N/A) |
36.26 (83.49) |
130.25% | Details | |
| 3/10/2022 | C4 Therapeutics | CCCC | New Coverage | Overweight (N/A) |
21.00 (3.04) |
-85.52% | Details | |
| 3/1/2022 | Revolution | RVMD | Maintain | Neutral (N/A) |
|
Details | ||
| 3/1/2022 | Novavax | NVAX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/1/2022 | Biomea Fusion Inc. | BMEA | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2022 | Beam Therapeutics Inc | BEAM | Maintain | Neutral (N/A) |
|
Details | ||
| 2/9/2022 | Karyopharm Therapeutics | KPTI | Upgrade | Neutral (Underweight) |
10.24 (8.77) |
-14.36% | Details | |
| 1/7/2022 | Aligos Therapeutics Inc. | ALGS | Downgrade | Neutral (Overweight) |
10.61 (6.98) |
-34.21% | Details | |
| 11/10/2021 | Achilles Therapeutics | ACHL | Maintain | Underweight (N/A) |
|
Details | ||
| 10/27/2021 | Myovant Sciences Ltd. | MYOV | Maintain | Overweight (N/A) |
|
Details | ||
| 10/20/2021 | Atea Pharmaceuticals | AVIR | Downgrade | Neutral (Overweight) |
40.60 (5.89) |
-85.49% | Details | |
| 10/8/2021 | Relay Therapeutics | RLAY | Upgrade | Overweight (Neutral) |
26.00 (9.89) |
-61.96% | Details | |
| 10/8/2021 | Omeros Corp. | OMER | Downgrade | Underweight (Neutral) |
7.21 (11.54) |
60.06% | Details | |
| 9/27/2021 | Omeros Corp. | OMER | New Coverage | Neutral (N/A) |
15.95 (7.21) |
-54.8% | Details | |
| 9/9/2021 | Humanigen | HGEN | Downgrade | Underweight (Neutral) |
15.11 (0.04) |
-99.74% | Details | |
| 8/18/2021 | Terns Pharmaceuticals | TERN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/17/2021 | Freeline | FRLN | Downgrade | Neutral (Overweight) |
3.35 (6.48) |
93.43% | Details | |
| 8/13/2021 | Relay Therapeutics | RLAY | Maintain | Neutral (N/A) |
|
Details | ||
| 8/10/2021 | Achilles Therapeutics | ACHL | Maintain | Underweight (N/A) |
|
Details | ||
| 8/6/2021 | Karyopharm Therapeutics | KPTI | Downgrade | Underweight (Overweight) |
7.82 (8.77) |
12.15% | Details | |
| 7/29/2021 | Myovant Sciences Ltd. | MYOV | Maintain | Overweight (N/A) |
|
Details | ||
| 7/21/2021 | Enanta Pharmaceuticals | ENTA | Maintain | Neutral (N/A) |
|
Details | ||
| 7/21/2021 | Myovant Sciences Ltd. | MYOV | Maintain | Overweight (N/A) |
|
Details | ||
| 7/19/2021 | Monte Rosa Therapeutics | GLUE | New Coverage | Overweight (N/A) |
19.12 (17.80) |
-6.9% | Details | |
| 7/13/2021 | Century Therapeutics | IPSC | New Coverage | Overweight (N/A) |
27.61 (2.56) |
-90.73% | Details | |
| 7/12/2021 | Verve Therapeutics | VERV | New Coverage | Neutral (N/A) |
46.25 (11.13) |
-75.94% | Details | |
| 5/20/2021 | Black Diamond Therapeutics | BDTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/14/2021 | Beam Inc | BEAM | Maintain | Neutral (N/A) |
|
Details | ||
| 5/12/2021 | Novavax | NVAX | Downgrade | Neutral (Overweight) |
138.18 (9.98) |
-92.78% | Details | |
| 5/11/2021 | Biomea Fusion Inc. | BMEA | New Coverage | Overweight (N/A) |
16.94 (1.39) |
-91.79% | Details | |
| 5/10/2021 | Black Diamond Therapeutics | BDTX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/25/2021 | Black Diamond Therapeutics | BDTX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/4/2021 | Five Prime Therapeutics | FPRX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/2/2021 | Terns Pharmaceuticals | TERN | New Coverage | Overweight (N/A) |
24.64 (42.82) |
73.78% | Details | |
| 2/25/2021 | Rocket Pharmaceuticals | RCKT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/23/2021 | Humanigen | HGEN | New Coverage | Neutral (N/A) |
23.83 (0.04) |
-99.83% | Details | |
| 1/29/2021 | Novavax | NVAX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/29/2021 | Akebia Therapeutics | AKBA | Downgrade | Underweight (Neutral) |
3.49 (1.27) |
-63.61% | Details | |
| 1/29/2021 | Enanta Pharmaceuticals | ENTA | Upgrade | Neutral (Underweight) |
48.96 (13.54) |
-72.34% | Details | |
| 1/29/2021 | Beam Inc | BEAM | Downgrade | Neutral (Overweight) |
92.01 (26.54) |
-71.16% | Details | |
| 1/29/2021 | AUTL | AUTL | Downgrade | Neutral (Overweight) |
8.10 (1.51) |
-81.36% | Details | |
| 12/21/2020 | Myovant Sciences Ltd. | MYOV | Maintain | Overweight (N/A) |
|
Details | ||
| 11/23/2020 | Rocket Pharmaceuticals | RCKT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/16/2020 | Urovant Ltd. | UROV | Downgrade | Neutral (Overweight) |
8.28 (16.24) |
96.14% | Details | |
| 11/11/2020 | Five Prime Therapeutics | FPRX | Upgrade | Neutral (Underweight) |
5.49 (38.00) |
592.17% | Details | |
| 11/9/2020 | ObsEva | OBSV | Downgrade | Underweight (Neutral) |
1.97 (0.10) |
-94.92% | Details | |
| 10/15/2020 | Nurix | NRIX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/7/2020 | PTC Therapeutics | PTCT | Upgrade | Overweight (Neutral) |
49.97 (62.82) |
25.72% | Details | |
| 9/3/2020 | Akebia Therapeutics | AKBA | Downgrade | Neutral (Overweight) |
10.00 (1.27) |
-87.3% | Details | |
| 9/1/2020 | Freeline | FRLN | New Coverage | Overweight (N/A) |
16.15 (6.48) |
-59.88% | Details | |
| 9/1/2020 | TG Therapeutics | TGTX | New Coverage | Overweight (N/A) |
24.50 (29.27) |
19.47% | Details | |
| 8/19/2020 | Momenta Pharmaceuticals | MNTA | Downgrade | Neutral (Overweight) |
30.81 (52.48) |
70.33% | Details | |
| 8/17/2020 | Nurix | NRIX | New Coverage | Overweight (N/A) |
23.88 (15.10) |
-36.77% | Details | |
| 8/10/2020 | Relay Therapeutics | RLAY | New Coverage | Neutral (N/A) |
41.02 (26.00) |
-36.62% | Details | |
| 8/5/2020 | Novavax | NVAX | Upgrade | Overweight (Neutral) |
155.87 (138.18) |
-11.35% | Details | |
| 7/31/2020 | AUTL | AUTL | New Coverage | Overweight (N/A) |
13.20 (1.51) |
-88.56% | Details | |
| 7/7/2020 | ObsEva | OBSV | Downgrade | Neutral (Overweight) |
6.15 (0.10) |
-98.37% | Details | |
| 7/2/2020 | Rocket Pharmaceuticals | RCKT | New Coverage | Overweight (N/A) |
20.93 (2.33) |
-88.87% | Details | |
| 6/5/2020 | Novavax | NVAX | Upgrade | Neutral (Underweight) |
44.66 (9.98) |
-77.65% | Details | |
| 3/9/2020 | Revolution | RVMD | New Coverage | Neutral (N/A) |
32.98 (98.40) |
198.36% | Details | |
| 3/5/2020 | ObsEva | OBSV | Maintain | Overweight (N/A) |
|
Details | ||
| 3/2/2020 | Beam Inc | BEAM | New Coverage | Overweight (N/A) |
22.93 (26.54) |
15.74% | Details | |
| 2/28/2020 | Five Prime Therapeutics | FPRX | Downgrade | Underweight (Neutral) |
4.83 (38.00) |
686.75% | Details | |
| 2/24/2020 | Black Diamond Therapeutics | BDTX | New Coverage | Overweight (N/A) |
37.03 (2.15) |
-94.19% | Details | |
| 1/15/2020 | Momenta Pharmaceuticals | MNTA | Upgrade | Overweight (Neutral) |
20.50 (30.81) |
50.29% | Details | |
| 9/26/2019 | Enanta Pharmaceuticals | ENTA | Downgrade | Underweight (Neutral) |
71.82 (13.54) |
-81.15% | Details | |
| 7/23/2019 | Karyopharm Therapeutics | KPTI | Upgrade | Overweight (Neutral) |
8.30 (8.77) |
5.66% | Details | |
| 6/14/2019 | Melinta Therapeutics Inc. | MLNT | Downgrade | Underweight (Neutral) |
1.82 (0.50) |
-72.53% | Details | |
| 5/2/2019 | Akebia Therapeutics | AKBA | New Coverage | Overweight (N/A) |
6.04 (10.00) |
65.56% | Details | |
| 4/22/2019 | Precision BioSciences Inc. | DTIL | New Coverage | Overweight (N/A) |
12.18 (4.61) |
-62.15% | Details | |
| 3/5/2019 | ObsEva | OBSV | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2019 | Karyopharm Therapeutics | KPTI | Downgrade | Neutral (Overweight) |
4.40 (8.30) |
88.64% | Details | |
| 2/28/2019 | Novavax | NVAX | Downgrade | Underweight (Overweight) |
2.13 (9.98) |
368.54% | Details | |
| 1/4/2019 | Momenta Pharmaceuticals | MNTA | Downgrade | Neutral (Overweight) |
10.66 (20.50) |
92.31% | Details | |
| 11/14/2018 | Sangamo BioSciences | SGMO | Downgrade | Neutral (Overweight) |
10.00 (0.38) |
-96.2% | Details | |
| 11/7/2018 | Ironwood Pharmaceuticals | IRWD | Downgrade | Underweight (Neutral) |
14.13 (12.72) |
-9.98% | Details | |
| 10/3/2018 | PTC Therapeutics | PTCT | Maintain | Neutral (N/A) |
|
Details | ||
| 9/21/2018 | Novavax | NVAX | Upgrade | Overweight (Underweight) |
1.47 (2.13) |
44.9% | Details | |
| 9/13/2018 | ObsEva | OBSV | New Coverage | Overweight (N/A) |
14.49 (0.10) |
-99.31% | Details | |
| 9/13/2018 | Myovant Sciences Ltd. | MYOV | New Coverage | Overweight (N/A) |
23.12 (26.98) |
16.7% | Details |
